Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Australian Clinical Labs Ltd ( (AU:ACL) ) has provided an announcement.
Australian Clinical Labs Ltd announced the issuance of unquoted equity securities as part of an employee incentive scheme. This move involves the issuance of service rights and performance rights, which are not intended to be quoted on the ASX, indicating a strategic step to enhance employee engagement and retention.
The most recent analyst rating on (AU:ACL) stock is a Buy with a A$4.25 price target. To see the full list of analyst forecasts on Australian Clinical Labs Ltd stock, see the AU:ACL Stock Forecast page.
More about Australian Clinical Labs Ltd
Australian Clinical Labs Ltd operates in the healthcare industry, focusing on providing pathology services. The company is a significant player in the Australian market, offering a range of diagnostic services to support clinical decision-making.
Average Trading Volume: 927,021
Technical Sentiment Signal: Sell
Current Market Cap: A$536.1M
See more data about ACL stock on TipRanks’ Stock Analysis page.